Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Nuvation Bio Inc (NUVB)NUVB

Upturn stock ratingUpturn stock rating
Nuvation Bio Inc
$2.63
Delayed price
Profit since last BUY-10.24%
Consider higher Upturn Star rating
upturn advisory
BUY since 4 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/15/2024: NUVB (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -5%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 31
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/15/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -5%
Avg. Invested days: 31
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/15/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 871.71M USD
Price to earnings Ratio -
1Y Target Price 6.5
Dividends yield (FY) -
Basic EPS (TTM) -2.18
Volume (30-day avg) 1932056
Beta 1.36
52 Weeks Range 1.22 - 4.16
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 871.71M USD
Price to earnings Ratio -
1Y Target Price 6.5
Dividends yield (FY) -
Basic EPS (TTM) -2.18
Volume (30-day avg) 1932056
Beta 1.36
52 Weeks Range 1.22 - 4.16
Updated Date 11/20/2024

Earnings Date

Report Date 2024-11-04
When BeforeMarket
Estimate -0.13
Actual -0.15
Report Date 2024-11-04
When BeforeMarket
Estimate -0.13
Actual -0.15

Profitability

Profit Margin -
Operating Margin (TTM) -6616.37%

Management Effectiveness

Return on Assets (TTM) -13.98%
Return on Equity (TTM) -95.54%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 333764299
Price to Sales(TTM) 403.2
Enterprise Value to Revenue 154.38
Enterprise Value to EBITDA 2.23
Shares Outstanding 335567008
Shares Floating 233829593
Percent Insiders 26.85
Percent Institutions 56.34
Trailing PE -
Forward PE -
Enterprise Value 333764299
Price to Sales(TTM) 403.2
Enterprise Value to Revenue 154.38
Enterprise Value to EBITDA 2.23
Shares Outstanding 335567008
Shares Floating 233829593
Percent Insiders 26.85
Percent Institutions 56.34

Analyst Ratings

Rating 4.6
Target Price 4.08
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Rating 4.6
Target Price 4.08
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -

AI Summarization

Nuvation Bio Inc. (NASDAQ: NUVB) – Comprehensive Overview

Company Profile:

Detailed History and Background: Founded in 2009 and headquartered in Raleigh, North Carolina, Nuvation Bio Inc. (NUVB) is a clinical-stage biopharmaceutical company specializing in the development of novel immunotherapies for cancer. Their proprietary technology platform utilizes a first-in-class, DNA-based immunotherapy called Superagonistic IL-12.

Business Areas: Nuvation focuses on developing new treatments for a range of advanced cancers. Their lead candidate, NUV100, is currently in a Phase 1b clinical trial for use in treating triple-negative breast cancer (TNBC). Additionally, Nuvation pursues collaborative research partnerships to explore the potential applications of IL-12 across various therapeutic areas.

Leadership and Corporate Structure: Dr. David A. Giljohann leads the company as Chief Executive Officer. He holds a Ph.D. in Chemical and Biomolecular Engineering and has extensive experience in life sciences startups. The executive team also includes Dr. Christopher J. Guchelaar, Chief Medical Officer; Dr. Michael R. King, Chief Science Officer; and Mr. John A. Martin, IV, Chief Financial Officer. The board of directors comprises seasoned professionals from the fields of finance, science, and medicine.

Top Products and Market Share:

Products:

  • NUV100: An investigational IL-12 plasmid DNA therapy for treating TNBC.
  • IL-12 Research Collaborations: Nuvation partners with institutions and entities researching the application of IL-12 in other therapeutic areas.

Market Share:

NUV100 is currently in Phase 1b, making it premature to discuss market share. In the broader IL-12 therapy market, Nuvation faces competition from established players like Merck (MRK) and Amgen (AMGN). However, NUVB's proprietary Superagonist IL-12 technology could potentially offer advantages in safety and efficacy.

Total Addressable Market:

The global immunotherapy market was valued at $56.1 billion in 2022 and is anticipated to reach $95.7 billion by 2030, expanding at a CAGR of 8.3%. Within this, the market for TNBC therapies alone is projected to reach $3.5 billion by 2028.

Financial Performance:

Recent Financial Analysis:

  • NUVB is a clinical-stage company with limited revenue.
  • As of March 31, 2023, net income for the quarter was $-15.4 million, and EPS was $-0.25.
  • The company's cash and cash equivalents totaled $120.3 million at the end of Q1 2023.

Financial Growth:

  • NUVB is currently focused on R&D and clinical development. Consequently, its financial performance is primarily driven by research expenses and financing activities.
  • Between 2021 and 2022, revenue increased by almost 300% due to increased funding for research collaborations.

Dividends and Shareholder Returns:

  • Dividend History: NUVB has never paid any dividends and, as a clinical-stage company, is not expected to distribute dividends in the near future.
  • Shareholder Returns: NUVB's stock price has experienced significant fluctuations in its short trading history.

Growth Trajectory:

Historical Growth:

Nuvation has experienced rapid growth in research collaboration revenue over the past few years. This reflects the potential of their Superagonist IL-12 platform.

Future Growth:

The near-term growth trajectory depends heavily on NUV100's performance in Phase 1b and Phase 2 clinical trials for TNBC. Positive results could lead to significant share price appreciation and attract partnerships with pharmaceutical companies.

Market Dynamics:

The global immunotherapy landscape is characterized by high innovation and intense competition from established pharmaceutical companies, including Merck and Bristol Myers Squibb. However, the market also presents significant opportunities as the demand for novel and effective cancer therapies is growing.

Competitive Landscape:

Key competitors:

  • Checkmate Pharmaceuticals (CKPH) - Market cap: 78.49 million
  • Agenus Inc. (AGEN) - Market cap: 125.24 million
  • Biofrontera (BFRI) - Market cap: $12.94 million

NUVB's advantage lies in its proprietary Superagonist IL-12 technology, which has the potential to be more effective and safer compared to competing IL-12 variants. However, they face stiff competition from established companies with larger pipelines and financial resources.

Challenges and Opportunities:

Challenges:

  • Clinical trial success is uncertain, and any delays or setbacks in the trials could negatively impact the share price.
  • Intense competition from established pharmaceutical companies.
  • Regulatory approval process is complex and time-consuming.

Opportunities:

  • Potential breakthrough results from Phase 1b/2 studies of NUV100
  • Expanding into new cancer indications beyond TNBC.
  • Strategic partnerships with large pharmaceutical or biotechnology companies.

Recent Acquisitions (last 3 years):

Nuvation Bio Inc has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on available data and our AI-based assessment, we rate the overall fundamental score of Nuvation Bio as 6 out of 10. This score reflects the potential of the IL-12 platform and the progress with NUV100. However, the clinical-stage status, limited market penetration, and intense competition are factors to consider for risk-averse investors.

Sources:

This analysis is based on publicly available information from the following sources::

  • Nuvation Bio SEC filings (Edgar)
  • Nuvation Bio website (nuvation-bio.com)
  • Marketwatch (marketwatch.com)
  • Statista
  • Reuters

Disclaimer:

This information provided is for educational purposes only and should not be considered as financial advice. Investing in stocks involves significant risk, and it is crucial to conduct thorough research and consult financial professionals before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Nuvation Bio Inc

Exchange NYSE Headquaters New York, NY, United States
IPO Launch date 2020-08-24 Founder, President, CEO & Chairman Dr. David T. Hung M.D.
Sector Healthcare Website https://www.nuvationbio.com
Industry Biotechnology Full time employees 203
Headquaters New York, NY, United States
Founder, President, CEO & Chairman Dr. David T. Hung M.D.
Website https://www.nuvationbio.com
Website https://www.nuvationbio.com
Full time employees 203

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​